HeartFlow vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
HeartFlow creates AI-powered, non-invasive 3D models of coronary arteries from CT scans to guide treatment of coronary artery disease, with FDA clearance and coverage from major insurers including Cigna.
About
HeartFlow, Inc. is a Redwood City, California–based medical technology company founded in 2011 that applies artificial intelligence to cardiac imaging to transform the diagnosis and management of coronary artery disease (CAD). Its flagship HeartFlow FFRCT Analysis generates a personalized, color-coded 3D model of a patient's coronary arteries from a standard CT scan, calculating fractional flow reserve values non-invasively to identify which blockages actually restrict blood flow. The technology is backed by more than 600 peer-reviewed publications and has helped clinicians manage over 400,000 patients worldwide.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.